Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

21251
1
IO Biotech, Inc. IO Biotech Reports $22.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

21252
1
Urgent.ly Inc. Urgent.ly Reports 22% Revenue Decline in Q1 2025 Amid Customer Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

21253
1
SusGlobal Energy Corp. SusGlobal Energy Corp. Reports 87% Revenue Decline and Increased Losses for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

21254
1
Zoned Properties, Inc. Zoned Properties Reports 16.4% Revenue Growth to $974,552 in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21255
1
Theriva Biologics, Inc. Theriva Biologics Reports $4.3 Million Net Loss, Focuses on Oncology Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

21256
1
Leatt Corp Leatt Corporation Reports 45% Revenue Growth to $15.37 Million in Quarterly Results

Via official filing (AI summary) | about 1 year ago | 0 comments

21257
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports $3.9 Million Net Loss in Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

21258
1
DeFi Development Corp. DeFi Development Corp. Reports $287K Revenue, 30% Decline, and Strategic Shift to Subscription Services

Via official filing (AI summary) | about 1 year ago | 0 comments

21259
1
CREATIVE REALITIES, INC. Creative Realities Reports 21% Revenue Decline and Operating Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21260
1
Longduoduo Co Ltd Longduoduo Company Limited Reports Significant Revenue Decline and Net Loss for Q3 and Nine Months Ended March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21261
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports $4.5 Million Net Loss in Q1 2025, Seeks Additional Capital

Via official filing (AI summary) | about 1 year ago | 0 comments

21262
1
Maitong Sunshine Cultural Development Co., Ltd Maitong Sunshine Reports 59% Revenue Decline and Net Loss for Six Months Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21263
1
Inozyme Pharma, Inc. Inozyme Pharma Reports $28M Net Loss in Q1 2025, Announces Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

21264
1
Marathon Bancorp, Inc. /MD/ Marathon Bancorp Reports Net Income of $148,403 for Q1 2025, Significant Turnaround from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

21265
1
Verve Therapeutics, Inc. Verve Therapeutics Reports $32.98M Collaboration Revenue and $31.03M Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21266
1
Advanced Flower Capital Inc. Advanced Flower Capital Inc. Reports $4.1 Million Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21267
1
Scholar Rock Holding Corp Scholar Rock Reports $74.7 Million Net Loss in Q1 2025, Increases Focus on Apitegromab

Via official filing (AI summary) | about 1 year ago | 0 comments

21268
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $15M Revenue and $26.1M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21269
1
Climb Bio, Inc. Climb Bio Reports $20.8 Million Net Loss and Increased R&D Expenses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

21270
1
Benitec Biopharma Inc. Benitec Biopharma Reports $9.4 Million Net Loss for Quarter Ended March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21271
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports Net Income Turnaround and Strategic Advances in Kidney Disease Treatments

Via official filing (AI summary) | about 1 year ago | 0 comments

21272
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q1 2025 Financial Results with Improved Revenue and Reduced Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

21273
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports 12% Revenue Growth and Improved Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

21274
1
Charlotte's Web Holdings, Inc. Charlotte's Web Holdings Reports Q1 2025 Financial Results with Revenue Growth and Reduced Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

21275
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $20.8 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments